GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (OTCPK:CHEOF) » Definitions » ROE % Adjusted to Book Value

Cochlear (Cochlear) ROE % Adjusted to Book Value : 1.98% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Cochlear ROE % Adjusted to Book Value?

Cochlear's ROE % for the quarter that ended in Dec. 2023 was 21.66%. Cochlear's PB Ratio for the quarter that ended in Dec. 2023 was 10.93. Cochlear's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 1.98%.


Cochlear ROE % Adjusted to Book Value Historical Data

The historical data trend for Cochlear's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cochlear ROE % Adjusted to Book Value Chart

Cochlear Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.43 -2.48 2.40 2.17 2.03

Cochlear Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.29 1.85 2.13 2.18 1.98

Competitive Comparison of Cochlear's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Cochlear's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cochlear's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cochlear's ROE % Adjusted to Book Value falls into.



Cochlear ROE % Adjusted to Book Value Calculation

Cochlear's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=17.11% / 8.41
=2.03%

Cochlear's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=21.66% / 10.93
=1.98%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cochlear ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cochlear's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cochlear (Cochlear) Business Description

Traded in Other Exchanges
Address
1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.